Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:47:51.276Z.
Calculation as of: 2026-10-06T21:47:51.276Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a98ef6549bf85b46c4ba181efc1584300b0c5a2a31302d891700dc780dc00a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$10.45M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.00M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.02M
Operating Cash Flow Yield
N/A
TTM Avg
28.18%
3Y Avg
28.18%
5Y Avg
28.18%
Market Cap
$11.08M
Operating Cash Flow Yield
N/A
TTM Avg
42.53%
3Y Avg
42.53%
5Y Avg
42.53%
Market Cap
$11.12M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pluri Inc. (PLUR) | $10.68M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | N/A | 28.18% | 28.18% | 28.18% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | N/A | 42.53% | 42.53% | 42.53% |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.21M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
